Lantheus (NASDAQ:LNTH) Price Target Raised to $85.00

Lantheus (NASDAQ:LNTH) had its price objective hoisted by Mizuho from $72.00 to $85.00 in a research report released on Friday morning,Benzinga reports. The firm currently has an outperform rating on the medical equipment provider’s stock.

LNTH has been the topic of several other research reports. Citigroup reaffirmed an “outperform” rating on shares of Lantheus in a report on Tuesday, February 24th. Citizens Jmp raised their price target on Lantheus from $73.00 to $78.00 and gave the stock a “market outperform” rating in a research note on Tuesday, February 24th. JonesTrading cut Lantheus from a “buy” rating to a “hold” rating in a research note on Friday. Truist Financial raised their target price on shares of Lantheus from $80.00 to $82.00 and gave the stock a “buy” rating in a research report on Thursday, December 18th. Finally, William Blair upgraded shares of Lantheus from a “market perform” rating to an “outperform” rating in a research report on Thursday. Seven analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, Lantheus presently has an average rating of “Moderate Buy” and a consensus target price of $82.17.

Lantheus Price Performance

LNTH stock opened at $74.91 on Friday. The business has a 50 day moving average price of $68.15 and a 200 day moving average price of $60.23. The company has a quick ratio of 2.51, a current ratio of 2.70 and a debt-to-equity ratio of 0.52. The stock has a market cap of $4.97 billion, a price-to-earnings ratio of 22.23 and a beta of -0.08. Lantheus has a fifty-two week low of $47.25 and a fifty-two week high of $111.29.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 26th. The medical equipment provider reported $1.67 earnings per share for the quarter, topping analysts’ consensus estimates of $1.17 by $0.50. Lantheus had a net margin of 15.15% and a return on equity of 30.77%. The company had revenue of $406.79 million for the quarter, compared to analysts’ expectations of $367.03 million. During the same quarter last year, the company earned $1.59 earnings per share. The firm’s revenue for the quarter was up 4.0% on a year-over-year basis. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. Equities research analysts anticipate that Lantheus will post 6.01 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

Institutional investors and hedge funds have recently made changes to their positions in the business. Smartleaf Asset Management LLC increased its holdings in Lantheus by 63.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock valued at $34,000 after acquiring an additional 197 shares in the last quarter. Parkside Financial Bank & Trust grew its position in shares of Lantheus by 20.2% in the second quarter. Parkside Financial Bank & Trust now owns 1,264 shares of the medical equipment provider’s stock valued at $103,000 after purchasing an additional 212 shares during the last quarter. First National Advisers LLC increased its stake in shares of Lantheus by 0.8% during the 2nd quarter. First National Advisers LLC now owns 27,995 shares of the medical equipment provider’s stock worth $2,292,000 after purchasing an additional 213 shares in the last quarter. Blue Trust Inc. raised its position in shares of Lantheus by 30.3% during the 4th quarter. Blue Trust Inc. now owns 990 shares of the medical equipment provider’s stock worth $66,000 after purchasing an additional 230 shares during the last quarter. Finally, Vident Advisory LLC lifted its stake in Lantheus by 0.5% in the 4th quarter. Vident Advisory LLC now owns 44,763 shares of the medical equipment provider’s stock valued at $2,979,000 after buying an additional 230 shares in the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

Trending Headlines about Lantheus

Here are the key news stories impacting Lantheus this week:

• Positive Sentiment: Q4 results: Lantheus reported $1.67 EPS vs. $1.17 expected and revenue of $406.8M vs. $367.0M expected (revenue +4% y/y), showing operational strength and margin improvement. MarketBeat Earnings Report
• Positive Sentiment: Mizuho raised its price target to $85 and set an “outperform” rating, signaling increased analyst conviction and implied upside from current levels. Benzinga
• Positive Sentiment: William Blair upgraded Lantheus from “market perform” to “outperform,” adding another positive analyst endorsement. Street Insider
• Positive Sentiment: Citizens Jmp raised its price target to $78, a modest endorsement that supports the view of upside among some sell‑side analysts. American Banking News
• Neutral Sentiment: JonesTrading reaffirmed a “hold” rating on LNTH, reflecting mixed views on near‑term catalysts. TickerReport
• Neutral Sentiment: Investor materials and transcripts are available (earnings call transcript and presentation), useful for digging into product trends, margin drivers and pipeline commentary. Yahoo Finance Transcript Seeking Alpha Deck
• Negative Sentiment: FY2026 guidance was mixed: EPS guidance of $5.00–$5.25 is roughly in line with consensus (5.16), but revenue guidance of $1.4B–$1.5B leaves room for a slight top‑line miss vs. expectations — a conservative revenue range that could weigh on near‑term sentiment. GlobeNewswire Press Release

Lantheus Company Profile

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.